Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov:13:348-355.
doi: 10.1016/j.ebiom.2016.10.032. Epub 2016 Oct 23.

The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial

Joseph Okebe  1 , Teun Bousema  2 , Muna Affara  3 , Gian Luca Di Tanna  4 , Edgard Dabira  5 , Abdoulaye Gaye  6 , Frank Sanya-Isijola  7 , Henry Badji  8 , Simon Correa  9 , Davis Nwakanma  10 , Jean-Pierre Van Geertruyden  11 , Chris Drakeley  12 , Umberto D'Alessandro  13
Affiliations
Randomized Controlled Trial

The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial

Joseph Okebe et al. EBioMedicine. 2016 Nov.

Abstract

Background: Asymptomatic low-density gametocyte carriers represent the majority of malaria-infected individuals. However, the impact of recommended treatment with single low dose of primaquine and an artemisinin-based combination therapy to reduce transmission in this group is unknown.

Methods: This was a four-arm, open label, randomized controlled trial comparing the effect of dihydroartemisinin-piperaquine (DHAP) alone or combined with single dose of primaquine (PQ) at 0.20mg/kg, 0.40mg/kg, or 0.75mg/kg on Plasmodium falciparum gametocytaemia, infectiousness to mosquitoes and hemoglobin change in asymptomatic, malaria-infected, glucose-6-phosphate dehydrogenase (G6PD) normal individuals. Randomization was done using a computer-generated sequence of uneven block sizes with codes concealed in sequentially numbered opaque envelopes. The primary endpoint was the prevalence of P. falciparum gametocytemia at day 7 of follow-up determined by quantitative nucleic acid sequence based assay and analysis was by intention to treat. The trial has been concluded (registration number: NCT01838902; https://clinicaltrials.gov/ct2/show/NCT01838902).

Results: A total of 694 asymptomatic, malaria-infected individuals were enrolled. Gametocyte prevalence at day 7 was 37.0% (54/146; 95% CI 29.2-45.4), 19.0% (27/142; 95% CI 12.9-26.4), 17.2% (25/145; 95% CI 11.0-23.5) and 10.6% (15/141; 95% CI 6.1-16.9) in the DHAP alone, 0.20mg/kg, 0.40mg/kg, and 0.75mg/kg PQ arms, respectively. The main adverse events reported include headache (130/471, 27.6%), cough (73/471, 15.5%), history of fever (61/471, 13.0%) and abdominal pain (57/471, 12.1%). There were five serious adverse events however, none was related to the interventions.

Interpretation: A single course of PQ significantly reduces gametocyte carriage in malaria-infected asymptomatic, G6PD-normal individuals without increasing the risk of clinical anemia. The limited number of successful mosquito infections suggests that post-treatment transmission potential in this asymptomatic population is low.

Keywords: Asymptomatic infection; Efficacy; Gametocyte carriage; Infectivity; Malaria; Plasmodium falciparum; Primaquine; Randomized trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of the study. DHAP: dihydroartemisinin-piperaquine, PQ: primaquine, QT-NASBA: quantitative nucleic acid sequence-based assay.
Fig. 2
Fig. 2
Gametocyte prevalence in each trial arms for each analyzed day of follow up. Error bars indicates the upper limit of the 95% confidence interval around the prevalence.
Fig. 3
Fig. 3
Odds ratio of gametocyte prevalence on each of the days of follow-up compared with the control arm adjusted for baseline gametocyte density. Bars indicate the upper and lower limits of the 95% confidence.
Fig. 4
Fig. 4
Kaplan Meier plot for gametocyte clearance in individuals who were gametocyte positive at enrolment.
See this image and copyright information in PMC

References

    1. Alves F., Gil L., Marrelli M., Ribolla P., Camargo E., Da silva L. Asymptomatic carriers of Plasmodium sp. as infection source for malaria vector mosquitoes in the Brazilian Amazon. J. Med. Entomol. 2005;42:777–779. - PubMed
    1. Ashley E.A., Recht J., White N.J. Primaquine: the risks and the benefits. Malar. J. 2014;13:418. - PMC - PubMed
    1. Bennett J.W., Pybus B.S., Yadava A., Tosh D., Sousa J.C., Mccarthy W.F., Deye G., Melendez V., Ockenhouse C.F. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N. Engl. J. Med. 2013;369:1381–1382. - PubMed
    1. Bereczky S., Montgomery S.M., Troye-blomberg M., Rooth I., Shaw M.A., Farnert A. Elevated anti-malarial IgE in asymptomatic individuals is associated with reduced risk for subsequent clinical malaria. Int. J. Parasitol. 2004;34:935–942. - PubMed
    1. Bousema T., Dinglasan R.R., Morlais I., Gouagna L.C., Van Warmerdam T., Awono-Ambene P.H., Bonnet S., Diallo M., Coulibaly M., Tchuinkam T., Mulder B., Targett G., Drakeley C., Sutherland C., Robert V., Doumbo O., Touré Y., Graves P.M., Roeffen W., Sauerwein R., Birkett A., Locke E., Morin M., Wu Y., Churcher T.S. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One. 2012;7 - PMC - PubMed

Publication types

MeSH terms

Associated data